Genzyme (GENZ) Receives Complete Response Letter From FDA For Lumizyme Application; Anticipates Negative Impact To 2009 Earnings
Tweet Send to a Friend
Genzyme Corporation (Nasdaq: GENZ) has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
